Gilead adds Assembly Biosciences (ASMB) shares through new stock grant

Rhea-AI Filing Summary

Gilead Sciences, Inc., a ten percent owner of Assembly Biosciences, Inc., reported receiving a grant or other acquisition of 471,698 shares of Common Stock on May 26, 2026 at $26.50 per share. After this award, Gilead directly holds 4,977,089 Assembly common shares.

Insider Trade Summary

Net Buyer: 471,698 shares

Net Buy 1 txn

Insider GILEAD SCIENCES, INC.

Role 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	471,698	$26.50	$12.50M

Holdings After Transaction: Common Stock — 4,977,089 shares (Direct)

Key Figures

Shares acquired: 471,698 shares Reported price per share: $26.50 per share Shares held after transaction: 4,977,089 shares

3 metrics

Shares acquired 471,698 shares Grant or award on May 26, 2026

Reported price per share $26.50 per share Value assigned to granted Assembly common stock

Shares held after transaction 4,977,089 shares Gilead’s direct Assembly common stock holdings post-transaction

Key Terms

ten percent owner, Common Stock, Grant, award, or other acquisition, Form 4

4 terms

ten percent owner regulatory

"the reporting person is marked as a ten percent owner of Assembly Biosciences"

Common Stock financial

"security title for the transaction is listed as Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description states Grant, award, or other acquisition"

Form 4 regulatory

"the insider transaction is reported on a Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 05/27/2026 - 08:55 PM Learn about SEC filing dates

FAQ

What insider transaction did Gilead report for ASMB?

Gilead Sciences reported acquiring 471,698 shares of Assembly Biosciences Common Stock as a grant or award. The transaction was dated May 26, 2026, and was reported on a Form 4 insider filing.

At what price were the new ASMB shares attributed to Gilead?

The newly acquired Assembly Biosciences shares were reported at a transaction price of $26.50 per share. This figure comes directly from the Form 4 and reflects the value used for the grant or award.

How many ASMB shares does Gilead hold after this transaction?

Following the reported grant or award, Gilead directly holds 4,977,089 shares of Assembly Biosciences Common Stock. This post-transaction holding total is explicitly stated in the Form 4 filing.

Was Gilead’s ASMB transaction an open-market purchase or a grant?

The Form 4 characterizes the event as a grant, award, or other acquisition, not an open-market purchase. It uses transaction code A, indicating a compensation-style or structured acquisition rather than a market buy.

What is Gilead’s status in relation to Assembly Biosciences (ASMB)?

Gilead Sciences is identified in the Form 4 as a ten percent owner of Assembly Biosciences. This status makes Gilead a reporting person for Section 16 purposes and requires disclosure of its qualifying share transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILEAD SCIENCES, INC.

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		A		471,698	A	$26.5	4,977,089	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)